Episode Details

High infection rates in UK, going down in US https://www.telegraph.co.uk/news/2021/10/19/people-must-cautious-day-to-day-interactions-covid-cases-climb/ Lower functional immunity in our population than most other Western European countries Early vaccine roll out AstraZeneca protects slightly less well than Pfizer against infection and transmission, particularly delta variant Slightly lower overall vaccination coverage, particularly vaccinating teenagers Fewer social restrictions High rates of testing UK, ONS https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights Two vaccine doses give similar protection as previous infection Two doses of either Pfizer-BioNTech or Oxford-AstraZeneca Provided a similar level of protection as having had a previous natural infection of coronavirus During delta variant times Vaccination reduced the risk of testing positive, both when the alpha variant was dominant in the UK (1 December 2020 to 16 May 2021) and when the delta variant was dominant (17 May to 14 August 2021) Two doses of Pfizer-BioNTech Reduced the risk of testing positive by 73% in the delta period Two doses of Oxford-AstraZeneca Reduced the risk of testing positive by 62% in the delta period Two vaccination doses, more effective than one at preventing symptomatic infection in both periods. Three weeks after vaccination Two doses always more protective than one (75% v 58%) Inconsistent with covid symptom study https://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covid Two doses of the Pfizer 87% protection against infection Two doses of the AstraZeneca 71% protection against infection Natural infection alone Only gave 65% protection against catching it again Israeli data consistent with ONS but inconsistent with covid symptom study Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdf Vaccination was highly effective Estimated efficacy for documented infection of 92·8% Hospitalization 94·2% Severe illness 94·4% Death 93·7% Protection from prior SARS-CoV-2 infection Estimated efficacy for documented infection of 94·8% Hospitalization 94·1% Severe illness 96·4% All deaths registered in the week to 8 October COVID-19 deaths fall in England, Northern Ireland and Scotland Up in Wales Total UK deaths in the week, 12,490 14.7% above the average in 2015 to 2019 820 involved the coronavirus (COVID-19) 154 fewer than the previous week Deaths involving COVID-19, 1 in 15 deaths (6.6%). UK total deaths include non-residents. 1 million people in UK countries had COVID-19 in the latest week 1.63% in England (1 in 60 people) One in 70 people the week before 2.18% in Wales (1 in 45 people) One in 55 people the week before 0.82% in Northern Ireland (1 in 120 people) One in 130 people the week before 1.26% in Scotland (1 in 80 people) One in 60 people the week before Greg and Peter Hello John, Just to let you know that one of my posts referring to your video on aspiration has been pulled from LinkedIn. This is the first time that one of my posts has been pulled and I have put out some pretty controversial posts on other subjects. Feedback from vaccine manufacturers

Learn more about your ad choices. Visit megaphone.fm/adchoices